paclitaxel / Generic mfg. - LARVOL DELTA

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Hoffmann-La Roche | Phase classification: P4 ➔ P3

Phase classification • Oncology

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P4 | N=1000 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial (IASLC-WCLC 2025) - "The IFCT-1805 ELDERLY trial assessed the addition of atezolizumab (ATZ), an ICI targeting the human programmed death-ligand 1 (PD-L1), to the current standard of care by monthly carboplatin with weekly paclitaxel CT (E Quoix et al, Lancet 2011) in elderly patients with advanced NSCLC. Conclusions : In the IFCT-1805 ELDERLY trial, despite a numerically longer OS when adding ATZ to the current standard of care CT for first line therapy of elderly patients with NSCLC, the gain was not statistically significant. However, the addition of ATZ to CT significantly improved the PFS, the ORR and the DOR regardless of PD-L1 expression."

Clinical • IO biomarker • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. (PubMed, Nat Commun) - P2 | "Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab...Non-resectable stage IIIA-IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles)...Grade ≥3 TRAEs occurred in 11 (28.9%) during induction, 10 (26.3%) during CT-RT, and 2 (5.3%) during maintenance. ChIO induction before CT-RT and IO maintenance showed activity and safety, warranting confirmation in larger studies."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

ACUTE TUBULAR INJURY WITH VACUOLIZATION AFTER PALBOCICLIB EXPOSURE IN A PATIENT WITH ADVANCED BREAST CANCER (ISN-WCN 2026) - "A 62-year-old woman with metastatic triple-positive breast cancer received paclitaxel, bevacizumab, and atezolizumab for two years to treat postoperative recurrence. CDK4/6 inhibition has been reported to impair autophagy, which may contribute to the observed tubular vacuolization and renal dysfunction. This case highlights a unique pattern of tubular injury potentially linked to autophagic disturbance caused by palbociclib."

Clinical • Metastases • Acute Kidney Injury • Breast Cancer • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Nephrology • Oncology • Renal Disease • Solid Tumor • CST3

IB 2019-07: Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. (clinicaltrialsregister.eu) - P1/2 | N=80 | Completed | Sponsor: Institut Bergonie | Active, not recruiting ➔ Completed

Biomarker • Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P4 trial • Oncology

SKYSCRAPER-05: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=50 | Terminated | Sponsor: Hoffmann-La Roche | Completed ➔ Terminated; Study was terminated as data became available from Phase 3 trials of perioperative regimens combining chemotherapy with immunotherapy showing improved efficacy outcomes versus chemotherapy alone.

Trial termination • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P4 | N=1000 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Dec 2028 ➔ Jul 2028 | Trial primary completion date: Dec 2028 ➔ Jul 2028

Trial completion date • Trial primary completion date • Oncology

Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer (ESMO 2025) - P3 | "The safety profile confirmed that atezo + CP is manageable. Conclusions The addition of atezo to CP did not demonstrate a statistically significant survival benefit in the overall population of pts with advanced/recurrent EC, but a substantial survival improvement was observed in pts with MMRd carcinomas."

Clinical • Combination therapy • Late-breaking abstract • Metastases • P3 data • Carcinosarcoma • Endometrial Cancer • Gynecologic Cancers • Oncology • Sarcoma

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology

Retrospective study for clinical biomarkers to guide post-EGFR-TKI treatment strategies in EGFR-mutant NSCLC (AACR 2026) - "Background: In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has demonstrated encouraging efficacy following prior treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs). Among patients with EGFR-mutant NSCLC previously treated with EGFR-TKIs, those with high PD-L1 expression may derive greater benefit from ABCP therapy compared with platinum-based chemotherapy, suggesting that ABCP could represent a more promising treatment option in this subgroup."

Biomarker • IO biomarker • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer. (PubMed, Clin Cancer Res) - "Safety results were generally consistent with known individual profiles for T-DXd and combination drugs. T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC."

Journal • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

Synthesis and evaluation of coumarin derivatives as potential anticancer therapies for colon cancer: In vitroantiproliferation, cell cycle arrest analyses, network pharmacology investigations, and molecular docking studies. (PubMed, Fitoterapia) - "Notably, when derivatives 24 and 25 were combined with paclitaxel, they significantly enhanced the S-phase cell cycle arrest...Docking analysis indicated that derivative 24 could activate CTNNB1 by interacting with the GLN-302 and ARG-342 residues of the protein. Derivatives 24 and 25 are promising anticancer drug candidates derived from natural products."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CTNNB1

Epoxyazadiradione, a neem-derived limonoid exhibits activities against pancreatic cancer through modulation of inflammatory molecules, lncRNAs, ROS, and EMT. (PubMed, Biochim Biophys Acta Gen Subj) - "It also enhanced the sensitivity of cell lines to paclitaxel, decreased the spheroid formation and modulated the expressions of EMT markers. These cumulative findings revealed that EPA exhibits anti-cancer activity against pancreatic cancer."

IO biomarker • Journal • Oncology • Pancreatic Cancer • Solid Tumor • ANXA5 • BAX • BCL2 • BCL2L1 • BIRC5 • GAS5 • MMP9

Blood-based proteomic profiling reveals context-dependent changes in BCL2-associated signaling during taxane therapy in breast cancer patients. (PubMed, FEBS Open Bio) - "To contextualize these observations, we generated Kaplan-Meier survival curves using publicly available proteomics data from The Cancer Proteome Atlas (TCPA). This work aims to demonstrate how blood-based proteomics can serve as a non-invasive method to monitor systemic physiological shifts during cancer therapy, offering a framework for generating hypotheses about chemotherapy timing and long-term outcomes."

IO biomarker • Journal • B Cell Lymphoma • Breast Cancer • Eye Cancer • Lymphoma • Oncology • Retinal Disorders • Solid Tumor • BCL2 • NLRP3 • RB1

N/2014/68: OSAGE : Phase I-II study chemoradiation in elderly patients with oesophagus cancer (clinicaltrialsregister.eu) - P1/2 | N=54 | Recruiting | Sponsor: Centre Hospitalier Regional Universitaire | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Oncology

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) (clinicaltrials.gov) - P3 | N=132 | Recruiting | Sponsor: Ente Ospedaliero Ospedali Galliera | Not yet recruiting ➔ Recruiting

Enrollment open • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • AR

C6461001: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrialsregister.eu) - P2/3 | N=203 | Not yet recruiting | Sponsor: Pfizer Inc.

New P2/3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (clinicaltrials.gov) - P2 | N=35 | Recruiting | Sponsor: The Third Xiangya Hospital of Central South University | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • HER-2 • ROS1

To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Unidade Local de Saúde São João

New trial • Head and Neck Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

BIPHASIC KIDNEY INJURY DUE TO BEVACIZUMAB- AND DOXORUBICIN-ASSOCIATED RENAL-LIMITED THROMBOTIC MICROANGIOGRAPHY: A CASE REPORT (ISN-WCN 2026) - "It may be difficult to distinguish drug-induced TMA from other primary TMAs, and the principal treatment is withdrawal of the causative drug, which requires early recognition.Methods We report the case of a 52-year-old woman with metastatic ovarian serous adenocarcinoma who developed biphasic kidney dysfunction during chemotherapy with bevacizumab and pegylated liposomal doxorubicin (PLD). The patient was diagnosed with ovarian cancer nine years earlier and underwent hysterectomy, oophorectomy, colectomy, and adjuvant paclitaxel–carboplatin therapy...Recognition of characteristic renal histopathological findings is crucial in differentiating drug-induced TMA from other etiologies. Timely diagnosis allows prompt cessation of the offending drug, which may preserve kidney function and optimize patient outcomes during chemotherapy."

Case report • Clinical • Glomerulonephritis • Gynecology • Lupus Nephritis • Nephrology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Renal Disease • Solid Tumor

IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MINIMAL CHANGE DISEASE - A CASE OF SUCCESSFUL RECHALLENGE (ISN-WCN 2026) - "After progression on carboplatin and paclitaxel, she was subsequently started on pembrolizumab, and demonstrated clinical response after three cycles, the last given 2 weeks before presentation...Given the temporal association and favorable oncologic response to ICI therapy, the diagnosis of MCD was attributed to pembrolizumab.ICI therapy was discontinued, and the patient was treated with oral prednisone 60 mg daily (tapered over 24 days) and rituximab (anti-CD20 antibody) 1 g IV given 2 weeks apart. Supportive therapy included bumetanide 1 g IV twice daily, losartan 12.5 mg daily, and atorvastatin 10 mg daily...In two cases, MCD relapsed following ICI re-challenge while in the third case, MCD remission was maintained with daily low-dose prednisone. Here, we report the first successful ICI re-challenge in a patient with ICI-associated MCD using a short course of low-dose prednisone bridging, achieving sustained renal remission and durable anti-tumor response."

Checkpoint inhibition • Clinical • CNS Disorders • Dyslipidemia • Endometrial Cancer • Glomerulonephritis • Immunology • Oncology • Solid Tumor

A CASE OF LATE-ONSET NEPHROTIC-RANGE PROTEINURIA CAUSED BY AN ANTI-ANGIOGENIC THERAPY FOR METASTATIC BREAST CANCER (ISN-WCN 2026) - "After changing to epirubicin/cyclophosphamide (EC) regimen, the patient's condition had been rather stable after 6 courses of EC therapy, when nausea and general malaise developed and worsened. Then, the regimen was changed to weekly paclitaxel plus bevacizumab (PTX/BEV) therapy...Because it was considered Grade 3 adverse events due to anti-angiogenic therapy, BEV was discontinued and the patient was followed with azilsartan and dapagliflozin...Conclusion The adverse events due to anti-angiogenic therapy are reported to be high, with proteinuria (∼10% to 60%) and hypertension being most prevalent. The interval between initiation of the therapy and the onset of proteinuria varies significantly (several weeks to ∼1 year), but the present case exhibited apparent proteinuria after 80 weeks of therapy. It is important to continuously follow up with close attention to renal function and urinalysis during and after anti-angiogenic therapy, even when the patient has remained..."

Clinical • Metastases • Breast Cancer • Hypertension • Nephrology • Oncology • Renal Disease • Solid Tumor